If efficacy data was the reason for this decision then J8 is correct - they should immediately go to jail. They say it is purely a commercial decision. However, as I said shareholder should be asking questions about Cohort 4 now that the trial will cease. They initially defined a positive material event has 2 x SVR but have since backed away from committing to this.
Based on continuous disclosure efficacy cannot be the reason but their muddled interpretation of efficacy demands this question be answered during the conference call on Tuesday.
